Development of replication-competent viral vectors for HIV vaccine delivery

Christopher L. Parks, Louis Picker, C. Richter King

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Purpose of Review: To briefly describe some of the replication-competent vectors being investigated for development of candidate HIV vaccines focusing primarily on technologies that have advanced to testing in macaques or have entered clinical trials. Recent Findings: Replication-competent viral vectors have advanced to the stage at which decisions can be made regarding the future development of HIV vaccines. The viruses being used as replication-competent vector platforms vary considerably, and their unique attributes make it possible to test multiple vaccine design concepts and also mimic various aspects of an HIV infection. Replication-competent viral vectors encoding simian immunodeficiency virus or HIV proteins can be used to safely immunize macaques, and in some cases, there is evidence of significant vaccine efficacy in challenge protection studies. Several live HIV vaccine vectors are in clinical trials to evaluate immunogenicity, safety, the effect of mucosal delivery, and potential effects of preexisting immunity. Summary: A variety of DNA and RNA viruses are being used to develop replication-competent viral vectors for HIV vaccine delivery. Multiple viral vector platforms have proven to be well tolerated and immunogenic with evidence of efficacy in macaques. Some of the more advanced HIV vaccine prototypes based on vesicular stomatitis virus, vaccinia virus, measles virus, and Sendai virus are in clinical trials.

Original languageEnglish (US)
Pages (from-to)402-411
Number of pages10
JournalCurrent Opinion in HIV and AIDS
Volume8
Issue number5
DOIs
StatePublished - Sep 2013

Fingerprint

AIDS Vaccines
Macaca
Clinical Trials
Vaccines
Viruses
Human Immunodeficiency Virus Proteins
Sendai virus
Simian Immunodeficiency Virus
Measles virus
Vesicular Stomatitis
DNA Viruses
Vaccinia virus
RNA Viruses
HIV Infections
Immunity
Technology
Safety

Keywords

  • HIV vaccine
  • replication-competent viral vectors
  • SIV challenge model

ASJC Scopus subject areas

  • Hematology
  • Oncology(nursing)
  • Immunology
  • Infectious Diseases
  • Virology
  • Oncology

Cite this

Development of replication-competent viral vectors for HIV vaccine delivery. / Parks, Christopher L.; Picker, Louis; King, C. Richter.

In: Current Opinion in HIV and AIDS, Vol. 8, No. 5, 09.2013, p. 402-411.

Research output: Contribution to journalArticle

Parks, Christopher L. ; Picker, Louis ; King, C. Richter. / Development of replication-competent viral vectors for HIV vaccine delivery. In: Current Opinion in HIV and AIDS. 2013 ; Vol. 8, No. 5. pp. 402-411.
@article{06de0aa107fe44638397b16fb48d728d,
title = "Development of replication-competent viral vectors for HIV vaccine delivery",
abstract = "Purpose of Review: To briefly describe some of the replication-competent vectors being investigated for development of candidate HIV vaccines focusing primarily on technologies that have advanced to testing in macaques or have entered clinical trials. Recent Findings: Replication-competent viral vectors have advanced to the stage at which decisions can be made regarding the future development of HIV vaccines. The viruses being used as replication-competent vector platforms vary considerably, and their unique attributes make it possible to test multiple vaccine design concepts and also mimic various aspects of an HIV infection. Replication-competent viral vectors encoding simian immunodeficiency virus or HIV proteins can be used to safely immunize macaques, and in some cases, there is evidence of significant vaccine efficacy in challenge protection studies. Several live HIV vaccine vectors are in clinical trials to evaluate immunogenicity, safety, the effect of mucosal delivery, and potential effects of preexisting immunity. Summary: A variety of DNA and RNA viruses are being used to develop replication-competent viral vectors for HIV vaccine delivery. Multiple viral vector platforms have proven to be well tolerated and immunogenic with evidence of efficacy in macaques. Some of the more advanced HIV vaccine prototypes based on vesicular stomatitis virus, vaccinia virus, measles virus, and Sendai virus are in clinical trials.",
keywords = "HIV vaccine, replication-competent viral vectors, SIV challenge model",
author = "Parks, {Christopher L.} and Louis Picker and King, {C. Richter}",
year = "2013",
month = "9",
doi = "10.1097/COH.0b013e328363d389",
language = "English (US)",
volume = "8",
pages = "402--411",
journal = "Current Opinion in HIV and AIDS",
issn = "1746-630X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Development of replication-competent viral vectors for HIV vaccine delivery

AU - Parks, Christopher L.

AU - Picker, Louis

AU - King, C. Richter

PY - 2013/9

Y1 - 2013/9

N2 - Purpose of Review: To briefly describe some of the replication-competent vectors being investigated for development of candidate HIV vaccines focusing primarily on technologies that have advanced to testing in macaques or have entered clinical trials. Recent Findings: Replication-competent viral vectors have advanced to the stage at which decisions can be made regarding the future development of HIV vaccines. The viruses being used as replication-competent vector platforms vary considerably, and their unique attributes make it possible to test multiple vaccine design concepts and also mimic various aspects of an HIV infection. Replication-competent viral vectors encoding simian immunodeficiency virus or HIV proteins can be used to safely immunize macaques, and in some cases, there is evidence of significant vaccine efficacy in challenge protection studies. Several live HIV vaccine vectors are in clinical trials to evaluate immunogenicity, safety, the effect of mucosal delivery, and potential effects of preexisting immunity. Summary: A variety of DNA and RNA viruses are being used to develop replication-competent viral vectors for HIV vaccine delivery. Multiple viral vector platforms have proven to be well tolerated and immunogenic with evidence of efficacy in macaques. Some of the more advanced HIV vaccine prototypes based on vesicular stomatitis virus, vaccinia virus, measles virus, and Sendai virus are in clinical trials.

AB - Purpose of Review: To briefly describe some of the replication-competent vectors being investigated for development of candidate HIV vaccines focusing primarily on technologies that have advanced to testing in macaques or have entered clinical trials. Recent Findings: Replication-competent viral vectors have advanced to the stage at which decisions can be made regarding the future development of HIV vaccines. The viruses being used as replication-competent vector platforms vary considerably, and their unique attributes make it possible to test multiple vaccine design concepts and also mimic various aspects of an HIV infection. Replication-competent viral vectors encoding simian immunodeficiency virus or HIV proteins can be used to safely immunize macaques, and in some cases, there is evidence of significant vaccine efficacy in challenge protection studies. Several live HIV vaccine vectors are in clinical trials to evaluate immunogenicity, safety, the effect of mucosal delivery, and potential effects of preexisting immunity. Summary: A variety of DNA and RNA viruses are being used to develop replication-competent viral vectors for HIV vaccine delivery. Multiple viral vector platforms have proven to be well tolerated and immunogenic with evidence of efficacy in macaques. Some of the more advanced HIV vaccine prototypes based on vesicular stomatitis virus, vaccinia virus, measles virus, and Sendai virus are in clinical trials.

KW - HIV vaccine

KW - replication-competent viral vectors

KW - SIV challenge model

UR - http://www.scopus.com/inward/record.url?scp=84883400877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883400877&partnerID=8YFLogxK

U2 - 10.1097/COH.0b013e328363d389

DO - 10.1097/COH.0b013e328363d389

M3 - Article

VL - 8

SP - 402

EP - 411

JO - Current Opinion in HIV and AIDS

JF - Current Opinion in HIV and AIDS

SN - 1746-630X

IS - 5

ER -